Replimune Group, Inc.
REPLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Replimune Group, Inc. (REPL) is listed under Biotechnology. At a $1.08B market cap, Replimune Group, Inc. ranks as a small-cap company within healthcare. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Market Cap
$1.08B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-6.30
EPS (TTM)
$-3.15
EPS (Fwd)
$-1.82
ROE
-134.3%
ROA
-51.3%
Cash
$195.3M
Total Debt
$112.0M
Free CF
-$171.7M
52W Change
30.2%
Annual Financials
Cash vs Debt
Where REPL stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, REPL finished 24.47% above its 150-day moving average ($9.44) and 29.98% above its 200-day moving average ($9.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is REPL overbought or oversold?
At the October 16, 2026 close, REPL's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $195.3M in cash comfortably exceeding the $112.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$171.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -134.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing REPL.